Key Highlights

  • Galectin Therapeutics executed a debt-to-equity conversion totaling approximately $105.8 million.
  • Chairman Richard Uihlein exchanged outstanding obligations for 34.4 million common shares at a weighted price of $3.07 each.
  • The move deleverages the balance sheet but expands the total share count to 100.8 million.
  • The transaction consolidates Uihlein's voting stake to roughly 44.3%.

Galectin Therapeutics (NASDAQ: GALT) executed a debt-to-equity conversion totaling approximately $105.8 million, with Chairman Richard Uihlein exchanging outstanding obligations for 34.4 million common shares at a weighted price of $3.07 each.

What Happened

While the move drastically deleverages the balance sheet, it expands the total share count to 100.8 million and consolidates Uihlein's voting stake to roughly 44.3%.

Market Reaction

The disclosed information does not include stock price or trading data for Galectin Therapeutics following the debt-to-equity conversion.

Outlook

The scale of Uihlein's consolidated voting stake, at roughly 44.3%, is likely to remain a relevant factor for investors assessing corporate governance and control dynamics at Galectin Therapeutics going forward.

What transaction did Galectin Therapeutics execute?

A debt-to-equity conversion totaling approximately $105.8 million, with Chairman Richard Uihlein exchanging obligations for 34.4 million common shares.

How does this affect the company's balance sheet?

It drastically deleverages the balance sheet, though it expands the total share count to 100.8 million.

What is Uihlein's resulting voting stake?

Roughly 44.3%.